Synairgen PLC on Tuesday said it had received positive data from its ACTIV-2 Phase 2 trial for its antiviral treatment.

The Southampton-based drug discovery and biotechnology company said fewer patients treated with its SNG001 treatment were hospitalised compared to participants given placebo. With SNG001, one out of 110 were hospitalised compared to seven out of 110 for placebo.

This was an 86% relative risk reduction but one that was not ‘statistically significant’, the company noted.

Synairgen said its treatment was ‘well-tolerated with a favourable safety profile’. The trial was conducted on home-based participants with Covid-19.

SNG001 is a formulation for inhalation containing the ‘broad-spectrum antiviral protein interferon beta’ to treat or prevent viral lung infections. This includes Covid-19.

Chief Executive Officer Richard Marsden said: ‘The data from the ACTIV-2 trial in the US showing a non-significant but encouraging 86% relative risk reduction in hospitalisation following treatment with SNG001 in home-based patients are very interesting when considered in the context of therapeutic options for the management of non-hospitalised patients during a pandemic.’

Shares in Synairgen were trading 0.7% higher at 16.27 pence each on Tuesday morning.

Copyright 2022 Alliance News Limited. All Rights Reserved.